Skip to main content
Delfa

← All assets

Crenezumab

9 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

9

Ongoing

0

Recruiting

0

Completed

6

Sites

459

Countries

41

Endpoints

163

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 163 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 1
1
Phase 2
5
Phase 3
3

Trials by status

Completed
6
Terminated
3

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Global cognition
27
Other (unclassified)
27
Amyloid biomarkers
21
Safety / tolerability / PK
18
Function / daily living
17
Behavior / neuropsychiatric
17
Neuroimaging
17
Memory
10
Caregiver / quality of life
4
Fluid / digital biomarkers
3
Tau biomarkers
2

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 36 of 163 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

ADAS-CogCognition

10

ADCS-Activities of Daily Living (ADCS-ADL)Function

9

Clinical Dementia Rating-Sum of Boxes (CDR-SB)Cognition

7

Mini-Mental State Examination (MMSE)Cognition

6

Neuropsychiatric Inventory (NPI)Behavior

4

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

9 of 9

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
CREAD 2A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)

Crenezumab

Alzheimer’s disease

prodromal ADPh 3Terminated211Jun 20194results
CREADA Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).

Crenezumab

Alzheimer’s disease

prodromal ADPh 3Terminated196May 20194results
NCT01343966A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Crenezumab

Alzheimer’s disease

Alzheimer's diseasePh 2Completed92Feb 20142
NCT01723826A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab

Crenezumab

Alzheimer’s disease

Alzheimer's diseasePh 2Completed86Feb 2017-results
CREAD OLEAn Open-Label Crenezumab Study in Participants With Alzheimer's Disease

Crenezumab

Alzheimer’s disease

Study partner/caregiver requiredPh 3Terminated66May 2019-results
NCT01397578A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

Crenezumab

Alzheimer’s disease

Alzheimer's diseasePh 2Completed29Apr 20143
NCT02353598A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease

Crenezumab

Alzheimer’s disease

mild-to-moderate ADPh 1Completed13Nov 20162
NCT01998841A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort

Crenezumab

Alzheimer’s disease

PSEN1 mutation requiredPh 2Completed4Mar 20223results
NCT03977584Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease

Crenezumab

Alzheimer’s disease

Age 30-60Ph 2Completed1Apr 2022-results

Showing 1-9 of 9 trials